Södertälje, Sweden, 9 November 2021 – Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra Bevan MSc.
Sandra brings 25 years’ experience in strategic and operational global drug development from Pharmaceutical and Biotech companies. Sandra served 17 years at AstraZeneca in global clinical development and cross-functional project management positions. For the past 8 years she has been the owner and Senior Pharmaceutical Development Consultant at Bevan Consulting AB. One of her core strengths is building and leading clinical teams, in all phases of clinical development. Sandra received her MSc in Health Sciences from The University of York, UK. Prior to joining the industry, she worked as a Registered Nurse in the UK’s NHS.
Anocca’s CEO and co-founder Reagan Jarvis, said, “We’re delighted that Sandra has joined us as our Head of Clinical Development, as we focus on moving our unique approach to generating novel TCR-T therapeutics towards the clinic.”
Anocca’s Head of Clinical Development, Sandra Bevan, said, “It is a real pleasure and an inspiring opportunity to join Anocca, and I’m looking forward to using my experience to take Anocca’s unique innovative approach to deciphering T cell immunity towards clinical development.”
We use cookies to ensure that we give you the best experience on our website.